← All trials
NCT04973306
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 31, 2021
- Primary completion
- Jul 31, 2024
- Completion date
- Jul 31, 2027
- First posted
- Jul 22, 2021
- Last posted
- Jul 22, 2021
- Enrollment
- 176
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Fudan UniversityLead sponsor
- Chinese Academy of Medical SciencesCollaborator
- Fudan UniversityOverall official - principal investigator
- Tianjin Medical UniversityCollaborator
- Shanghai Xuhui District Central HospitalCollaborator
- Jiao Tong UniversityCollaborator
- Fudan UniversityCollaborator
- Chinese Academy of Medical SciencesCollaborator
- Chinese Academy of Medical SciencesCollaborator
- Wenzhou Medical UniversityCollaborator
- The First People's Hospital of ChangzhouCollaborator
- Ningbo Medical Center Lihuili Eastern HospitalCollaborator
- Fudan UniversityCollaborator
- Shanghai Qingpu Central HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.